The following projects are indirectly supporting the In Silico World initiative, by allowing some of the effort assigned in those projects to the Alma Mater Studiorum – University of Bologna to the development and management of the InSilicoWorld Community of Practice.
STriTuVaD In Silico Trial for Tuberculosis Vaccine Development
This project aims to extend the Universal Immune System Simulator (UISS) developed by the University of Catania, to model the disease progression of active tuberculosis, and the mechanism of action of new therapeutic vaccines currently under clinical testing. The resulting code (UISS-TB) will be subjected to an extensive credibility assessment, including a prospective clinical validation.
Mobilise-D Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
This very large IMI project aims to develop and qualify with major regulators for the use in drug trials, a next-generation algorithm for the extraction of Digital Mobility Outcomes from the signals recorded by wearable Inertial Measurement Units.
CompBioMed A Centre of Excellence in Computational Biomedicine
This centre of excellence aims to provide a hub for practitioners in the field who need support to improve the scalability and the computational efficiency of their Computational Medicine solutions.
PRIMAGE PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers
PRIMAGE implements the latest advancement of in-silico imaging biomarkers and modelling of tumour growth towards a personalised diagnosis, prognosis and therapies follow-up in the clinical management of two pediatric cancers, Neuroblastoma and the Diffuse Intrinsic Pontine Glioma.
Running research projects
Here below a list of funded research projects that are, in our opinion, contributing to the lowering of the barriers that prevent a wider adoption of In Silico Trials. If you believe your project should be listed here, please contact us at email@example.com.
INSIST: In Silico Clinical Trials for treatment of Acute ischemic stroke
Developing simulator for thrombectomy; expect to use it for the CE marking of new medical devices for such operation. Present model credibility based on VV-40.
SILICOFCM: In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy
The project is developing a platform for the development and simulation of patient-specific models of the heart, to be used to evaluate the safety and efficacy of new interventions. They plan to validate according to VV-40, and also pursue the SaMD pathway, presumably for digital patient applications. Unclear how they will get qualification from EMA to support drug development.
INSILC: In-silico trials for drug-eluting BVS design, development and evaluation
InSilc is developing a platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS) and drug-eluting stents (DES). For the IST part, they plan to pursue this as supporting digital evidence to the regulatory evaluation of new drug-eluting BVS/DES designs, with credibility documented according to ASME V&V4.
REPOTRIAL: Setting standards for in silico drug repurposing
In silico repurposing of a combination of three known drugs has been validated in animal models of ischemic stroke. Scientific Advice for the first clinical study has been obtained from the German Federal Institute for Drugs and Medical Devices (BfArM). A different drug combination will be tested in a clinical trial for a form of chronic heart failure.